Cases & Deals

Share

Atlas Venture invests in Novexel

January 2007

Client(s) Atlas Venture

Jones Day advised Atlas Venture in connection with its purchase of €50 million ($64.6 million) of Series B Convertible Preferred Stock in a private placement by Novexel SA, a pharmaceutical company focused on the discovery and development of novel antibiotics and anti-fungals.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.